NLTX vs. RLMD, ACET, FGEN, CRVS, ALLK, NVCT, ADAG, KPTI, AMLX, and CTXR
Should you be buying Neoleukin Therapeutics stock or one of its competitors? The main competitors of Neoleukin Therapeutics include Relmada Therapeutics (RLMD), Adicet Bio (ACET), FibroGen (FGEN), Corvus Pharmaceuticals (CRVS), Allakos (ALLK), Nuvectis Pharma (NVCT), Adagene (ADAG), Karyopharm Therapeutics (KPTI), Amylyx Pharmaceuticals (AMLX), and Citius Pharmaceuticals (CTXR). These companies are all part of the "pharmaceutical preparations" industry.
Neoleukin Therapeutics (NASDAQ:NLTX) and Relmada Therapeutics (NASDAQ:RLMD) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, media sentiment, community ranking, risk, earnings, institutional ownership, analyst recommendations, valuation and profitability.
Neoleukin Therapeutics received 34 more outperform votes than Relmada Therapeutics when rated by MarketBeat users. Likewise, 45.87% of users gave Neoleukin Therapeutics an outperform vote while only 41.03% of users gave Relmada Therapeutics an outperform vote.
Neoleukin Therapeutics' return on equity of -37.22% beat Relmada Therapeutics' return on equity.
Relmada Therapeutics has a consensus target price of $25.00, suggesting a potential upside of 733.33%. Given Relmada Therapeutics' higher possible upside, analysts plainly believe Relmada Therapeutics is more favorable than Neoleukin Therapeutics.
In the previous week, Relmada Therapeutics had 3 more articles in the media than Neoleukin Therapeutics. MarketBeat recorded 3 mentions for Relmada Therapeutics and 0 mentions for Neoleukin Therapeutics. Relmada Therapeutics' average media sentiment score of 0.58 beat Neoleukin Therapeutics' score of 0.00 indicating that Relmada Therapeutics is being referred to more favorably in the news media.
Neoleukin Therapeutics has a beta of 1.11, indicating that its stock price is 11% more volatile than the S&P 500. Comparatively, Relmada Therapeutics has a beta of 0.27, indicating that its stock price is 73% less volatile than the S&P 500.
52.4% of Neoleukin Therapeutics shares are held by institutional investors. Comparatively, 45.2% of Relmada Therapeutics shares are held by institutional investors. 1.6% of Neoleukin Therapeutics shares are held by company insiders. Comparatively, 18.0% of Relmada Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than Relmada Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Neoleukin Therapeutics beats Relmada Therapeutics on 8 of the 13 factors compared between the two stocks.
Get Neoleukin Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for NLTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NLTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Neoleukin Therapeutics Competitors List
Related Companies and Tools
